LGNZZ 財務： Ligand Pharmaceuticals Inc AI 分析

Q: Ligand Pharmaceuticals Inc 的關鍵財務報表是什麼？

根據最新的財務報表（Form-10K），Ligand Pharmaceuticals Inc 的總資產為 $941，淨損失為 $-4

Q: LGNZZ 的關鍵財務比率是什麼？

Ligand Pharmaceuticals Inc 的流動比率為 8.47，淨利潤率為 -2.39，每股銷售為 $9.13。

Q: Ligand Pharmaceuticals Inc 的收入按細分市場或地理位置如何劃分？

Ligand Pharmaceuticals Inc 最大收入來源為 Biopharmaceutical，在最近的收益報告中收入為 167,133,000。就地區而言，United States 是 Ligand Pharmaceuticals Inc 的主要市場，收入為 167,133,000。

Q: Ligand Pharmaceuticals Inc 是否盈利？

無，根據最新的財務報表，Ligand Pharmaceuticals Inc 的淨損失為 $-4

Q: Ligand Pharmaceuticals Inc 有負債嗎？

是的，Ligand Pharmaceuticals Inc 的負債為 111

Q: Ligand Pharmaceuticals Inc 的流通股有多少？

Ligand Pharmaceuticals Inc 的總流通股為 19.1

首頁

股票

LGNZZ

LGNZZ 財務

Ligand Pharmaceuticals Inc

$0.07

-2.77%

$0

截至今日：Jan 27, 15:43:05 GMT-5

概觀預測收益股利財務狀況

收入

資產負債表

現金流量

年度

每季

LGNZZ 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	251	167	131	196	277	186
營收年增率 (YoY)	65%	27%	-33%	-28.99%	49%	55%
營收成本	14	11	10	52	62	30
毛利	236	156	120	143	215	156
銷售、一般及管理費用	93	78	52	70	57	64
研發	82	21	24	36	69	59
營業費用	207	133	110	140	136	147
其他非營業收入 (費用)	-8	-54	-2	0	-1	0
稅前淨利	62	2	63	36	47	-10
所得稅費用	14	6	9	41	-9	-7
淨利	48	-4	52	-33	57	-3
淨利成長	7%	-108%	-258%	-158%	-2,000%	-100%
稀釋後流通股數	20.62	18.29	17.75	16.9	17.2	16.2
股數年變動 (YoY)	12%	3%	5%	-2%	6%	-18%
每股盈餘 (稀釋)	2.35	-0.22	2.93	-1.97	3.31	-0.18
每股盈餘成長率	-4%	-108%	-249%	-160%	-1,939%	-101%
自由現金流	30	95	-14	120	70	50
每股自由現金流	--	--	--	--	--	--
毛利率	94.02%	93.41%	91.6%	72.95%	77.61%	83.87%
營業利益率	11.15%	13.77%	6.87%	1.53%	28.15%	4.3%
淨利率	19.12%	-2.39%	39.69%	-16.83%	20.57%	-1.61%
自由現金流利潤率	11.95%	56.88%	-10.68%	61.22%	25.27%	26.88%
EBITDA	62	55	42	37	125	31
EBITDA 利潤率	24.7%	32.93%	32.06%	18.87%	45.12%	16.66%
EBITDA 中的折舊與攤銷	34	32	33	34	47	23
EBIT	28	23	9	3	78	8
EBIT 利潤率	11.15%	13.77%	6.87%	1.53%	28.15%	4.3%
有效稅率	22.58%	300%	14.28%	113.88%	-19.14%	70%

Follow-Up Questions

Ligand Pharmaceuticals Inc 的關鍵財務報表是什麼？



LGNZZ 的關鍵財務比率是什麼？



Ligand Pharmaceuticals Inc 的收入按細分市場或地理位置如何劃分？



Ligand Pharmaceuticals Inc 是否盈利？



Ligand Pharmaceuticals Inc 有負債嗎？



Ligand Pharmaceuticals Inc 的流通股有多少？



關鍵數據

前收市價

$0.072

開盤價

$0.07

當日範圍

$0.07 - $0.07

52週區間

$0.07 - $0.17

交易量

3.0K

平均成交量

50.0K

每股盈餘 (TTM)

2.78

股息收益率

市值

$1.3M

什麼是 LGNZZ？

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in Jupiter, Florida and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

功能特性

交易策略